Following the success of the blockbuster anti-cancer drug DARZALEX (daratumumab), Genmab is developing a pipeline of proprietary antibodies. Anthony Pagano, the Danish firm’s new CFO, tells flow’s Janet Du Chenne
how the company’s US capital raising fits that strategy
Across three core sites in Copenhagen, Utrecht and New Jersey, teams of scientists at Genmab are working to develop seven antibodies for the treatment of cancer.
Three of the Copenhagen-headquartered biotech company’s antibodies are already on the market with partners. The first, DARZALEX (daratumumab), developed by Janssen Biotech, has become a blockbuster drug for the treatment of multiple myeloma, a type of bone marrow cancer that forms on white blood cells.1 The second, ARZERRA (ofatumumab), developed by Novartis, treats chronic lymphocytic leukaemia.2 The third, TEPEZZA (teprotumumab-trbw), developed by Horizon Therapeutics, was approved in January 2020 to treat thyroid eye disease.
DARZALEX data was first presented in June 2012, when encouraging preliminary results were reported from a clinical trial in relapsed multiple myeloma patients. It achieved international acclaim in August 2012, when Genmab granted Janssen Biotech, a subsidiary of US group Johnson & Johnson, an exclusive worldwide licence to develop, manufacture and commercialise the drug in exchange for a royalty fee of 12−20% per net sales.3 Following the license of worldwide commercialisation rights of the treatment, Genmab CEO Jan van de Winkel leveraged this success to build a strong foundation for the future, beyond DARZALEX.
Find out more about products and services
flow magazine is published twice per year and can be read online and delivered to your door in print